Key result
Rivaroxaban and dabigatran etexilate are effective new oral anticoagulants that offer potential advantages over heparin and warfarin for preventing venous thrombosis after knee or hip replacement.
Why the study?
What are the mechanisms of action of new oral anticoagulant drugs (rivaroxaban and dabigatran etexilate) for the prevention of venous thrombosis after elective knee or hip replacement?
Population
Patients undergoing elective knee or hip replacement
Comparison
New oral anticoagulant drugs vs Heparin and warfarin
Design
Review
Authors
Loading...
May support VTE prophylaxis after joint replacement; leaves open need for head-to-head RCTs and long-term safety data.
What are the mechanisms of action of new oral anticoagulant drugs (rivaroxaban and dabigatran etexilate) for the prevention of venous thrombosis after elective knee or hip replacement?
Rivaroxaban and dabigatran etexilate are effective new oral anticoagulants with distinct mechanisms of action that offer potential advantages over traditional therapies like heparin and warfarin.
Timothy Brighton (2010) conducted a review in Venous thrombosis after elective knee or hip replacement. New oral anticoagulant drugs (rivaroxaban and dabigatran etexilate) vs. Heparin and warfarin was evaluated. Rivaroxaban and dabigatran etexilate are effective new oral anticoagulants that offer potential advantages over heparin and warfarin for preventing venous thrombosis after knee or hip replacement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: